Merial Animal Health Launches Its New Feline Vaccine PUREVAX® Rabies In The UK And Ireland

Merial Animal Health is pleased to announce the launch of its new feline vaccine PUREVAX® Rabies in the UK and Ireland. PUREVAX Rabies is an exciting new addition to Merial’s existing feline vaccine range. Based on Merial’s advanced canarypox vector technology, the product offers a simple yet elegant solution to rabies vaccination, without the need for adjuvant. The non-replicative vector is processed by the cat’s immune system in the same way as a live virus, triggering both a powerful cell mediated and humoral response without the need for adjuvant. Yet, because the vector cannot replicate effectively in mammalian cells, there is no risk of any reversion to virulence. Commenting on this latest addition to the PUREVAX range, Merial’s Veterinary Technical Manager Kevin Whelan, said “This is a perfect complement to our existing range of advanced technology vaccines, which already offer the benefits of highly effective protection, including updated FCV strains, without the need for adjuvant. It also represents Merial’s continued commitment to the development of innovative products for the animal health market”. The vaccine is licensed for use in cats from 12 weeks of age, and administration of a single injection has been shown to provide protection against disease. Please contact your local Merial Representative or the Merial Technical Support line on 0870 6000 123 for further information.

More from

• Animus launches SkinBond Multi for enhanced wound care
• IVC Evidensia reports 82% cut in Farm antibiotic use and 20% carbon emissions reduction
• Vet professionals flock to sign up to transformative locum platform
• The ProSalus Foundation launches urgent appeal for UK vets to support Ukrainian colleagues
• Vetsure Named Business of the Year at 2025 SME National Business Awards